Results 41 to 50 of about 32,846 (250)

418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss

Journal of Clinical and Translational Science, 2022
OBJECTIVES/GOALS: We aimed to determine if GLP-1 receptor agonists exert beneficial effects on surrogate measures of cardiovascular function independently of weight loss.
Mona Mashayekhi, Joshua A. Beckman, Erica M. Garner, Hui Nian, Chang Yu, Sara E. Howard, Bradley Perkins, Jessica K. Devin, John R. Koethe, Jonathan D. Brown, Heidi Silver, James M. Luther, Nancy J. Brown   +12 more
doaj   +1 more source

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial [PDF]

, 2009
Udgivelsesdato: 2009-OctAIMS/HYPOTHESIS: The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and ...
D. Russell-Jones, null null, A. Vaag, O. Schmitz, B. K. Sethi, N. Lalic, S. Antic, M. Zdravkovic, G. M. Ravn, R. Simó   +9 more
core   +1 more source

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

PLoS ONE, 2018
BackgroundWe assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden.MethodsThe Swedish Institute for Health
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P Jansen, Adam Fridhammar   +4 more
doaj   +1 more source

Evidence review : liraglutide for the treatment of type 2 diabetes [PDF]

, 2011
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute
Cummins, E. (Ewen), HASH(0x5574f4171138), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +4 more
core  

Zinc‐Containing Bioactive Glass Programs Macrophage Polarization through Extracellular Traps Regulation for Enhanced Diabetic Wound Healing

Advanced Healthcare Materials, EarlyView.
Zinc‐containing bioactive glass (ZnBG) promotes diabetic wound healing by regulating macrophage extracellular traps (METs). Specifically, ZnBG reduces oxidative stress and inhibits the PAD4 and NLRP3/caspase‐1/GSDMD signaling pathways, thereby suppressing MET formation.
RuiYang Sun, XueBo Wei, ZhuoYang Song, JunJun Luo, JingYi Ye, YinNan Zhang, LiFei Zhu, Jie Gao, Hongyu Zhang, Hong Zhu, Xin Wang, Ke Xu   +11 more
wiley   +1 more source

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

Scientific Reports, 2017
Hepatic stellate cells (HSC) play a key role in the development of chronic liver disease (CLD). Liraglutide, well-established in type 2 diabetes, showed anti-inflammatory and anti-oxidant properties.
Fernanda Cristina de Mesquita, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Raquel Maeso-Díaz, Sergi Vila, Diana Hide, Martí Ortega-Ribera, José Luís Rosa, Juan Carlos García-Pagán, Jaime Bosch, Jarbas Rodrigues de Oliveira, Jordi Gracia-Sancho   +11 more
doaj   +1 more source

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal [PDF]

, 2011
This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National ...
Cummins, E. (Ewen), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +3 more
core  

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi, Anetzberger, Anichini, Aoyama, Baggio, Balint, Ban, Beckman, Bouxsein, Brunton, Chen, Coleman, Dempster, Ealey, Eckel, Feng, Flatt, Friedman, Griffith, Griffith, Hamilton, Hu, Karim, Kim, Lee, Lu, Ma, Mabilleau, Mabilleau, Mansur, Marenzana, Mieczkowska, Napoli, Nuche-Berenguer, Nuche-Berenguer, Nuche-Berenguer, Nystrom, Nystrom, Odgaard, Okerson, Orland, Orriss, Paschalis, Pereira, Pereira, Prisby, Richard, Roche, Roszer, Schalkwijk, Scheller, Selley, Shymkiw, Smits, Stabley, Sun, Tartaglia, Upadhyay, van Bloemendaal, Vijan, Williams, Wu, Yamamoto, Yamamoto, Yamamoto   +64 more
core   +6 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Liraglutide inhibits the development of colorectal cancer by regulating TGF-β/Smad3 signaling pathway and affecting epithelial-mesenchymal transition

Discover Oncology
Background Liraglutide, a glucagon-like peptide-1 receptor agonist commonly used in diabetes management, has shown potential anti-cancer effects across various malignancies.
Xinjian Li, Minghu Fan, Rong Huang, Keqiang Wang, Hunan Huang   +4 more
doaj   +1 more source